Short Interest in Vivos Therapeutics, Inc. (NASDAQ:VVOS) Expands By 921.9%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 191,100 shares, a growth of 921.9% from the March 31st total of 18,700 shares. Based on an average daily trading volume, of 210,400 shares, the days-to-cover ratio is currently 0.9 days. Approximately 7.6% of the shares of the company are sold short.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Vivos Therapeutics stock. Armistice Capital LLC purchased a new stake in Vivos Therapeutics, Inc. (NASDAQ:VVOS) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 57,000 shares of the company’s stock, valued at approximately $709,000. Armistice Capital LLC owned approximately 4.29% of Vivos Therapeutics as of its most recent SEC filing. 26.35% of the stock is owned by institutional investors.

Vivos Therapeutics Price Performance

VVOS stock traded down $0.10 during midday trading on Thursday, reaching $2.47. The company had a trading volume of 45,277 shares, compared to its average volume of 186,761. The company has a market capitalization of $7.36 million, a price-to-earnings ratio of -0.23 and a beta of 7.94. The stock has a 50 day moving average price of $4.16 and a 200-day moving average price of $6.80. Vivos Therapeutics has a 1-year low of $2.37 and a 1-year high of $48.79.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings results on Thursday, March 28th. The company reported ($3.05) EPS for the quarter. The company had revenue of $3.25 million during the quarter. Vivos Therapeutics had a negative net margin of 98.42% and a negative return on equity of 665.17%.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.